Cytokinetics, Incorporated

CYTK Healthcare Biotechnology

Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024. In the quarter to June 2026, revenue fell 57.1%, EPS fell 33.9%, free cash flow fell 24.0% and total debt rose 57.7%, each against the same quarter a year earlier.

61.95 1.97 −3.08%
Market cap
$8.9B
P/E
0.0×
Fwd P/E
−11.1×
Dividend yield
—
F-score
2/9
Altman Z
−1.98
Beneish M
−0.44
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

281.08% 197.47% 151.81% 329.76%
Piotroski F-Score
3 2 2 1
ROA
(52.35%) (55.55%) (65.39%) (56.76%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(82.52%) (98.90%) (114.79%) (80.83%)
Average Days of Receivables
7.57 73.65 23.55 131.78
Free Cash Flow per Share
(3.78) (4.45) (4.45) (4.40)
Free Cash Flow
(453.38) (534.82) (548.92) (580.71)
Other line items

Show all line items

Columns are period end dates